Statements & press releases26.03.26PFAS restrictions: risks for patients and companies operating in EuropeRead Article
EFPIA reaction to the publication of ECHA scientific committees’ opinions on PFAS Restriction. The p...
Publisher
EU
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
EFPIA reaction to the publication of ECHA scientific committees’ opinions on PFAS Restriction. The p...
Source route
Continue on efpia.eu
Leave the platform to read the original full article on the publisher site.
Source: EFPIA Europe
Scope: Regulatory
Related coverage
More related coverage
Generic Drug User Fee Amendments
This page features news and information for industry and stakeholders about GDUFA, its fee structure...
What’s New for Biologics
Latest news from the Center for Biologics Evaluation and Research
Switching Between Biosimilars and Their Reference Counterparts with Dr. Sarah Yim
Listen to our latest podcast series, Q&A with FDA, on Switching Between Biosimilars and Their Refere...
Decision: Medical devices given exceptional use authorisations
List of manufacturers and their medical devices granted an exemption by MHRA. The list also includes...